| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000031206 |
| Receipt No. | R000035617 |
| Official scientific title of the study | Safety of Overconsumption of a Test Food |
| Date of disclosure of the study information | 2018/02/09 |
| Last modified on | 2018/12/04 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Safety of Overconsumption of a Test Food | |
| Title of the study (Brief title) | Safety of Overconsumption of a Test Food | |
| Region |
|
|
| Condition | ||
| Condition | N/A(healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study examines safety of overconsumption (4 weeks) of a test food. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | [1]Existence and its contents of side effects: expression number and expression rate of side effects (expression rate: number of cases/number of cases analyzed) (Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . |
| Key secondary outcomes | *Secondary outcomes
[1]Adverse events: number of cases and expression rate of adverse events (expression rate: number of cases/number of cases analyzed) (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . [2]Blood pressure, pulsation (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . [3]Weight, body fat percentage, BMI (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . [4]Hematologic test (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . [5]Blood biochemical test (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . [6]Urine analysis (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . [7]Doctor's questions (Week 0, Week 2, Week 4, 2 weeks after the end of ingestion of a test food) . *Other index [1]Subject's diary (each day during the test period). |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral intake of the test product (354mL in a day for 4 weeks) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | [1]Males and females aged 20-65 years.
[2]Individuals who are healthy and have no chronic physical disease. [3]Individuals whose fasting blood glucose is over 100mg/dL, and less than 110mg/dL or over 110mg/dL, less than 126mg/dL. [4]Individuals whose BMI is over 18.5 and under 30. [5]Individuals whose written informed consent has been obtained. [6]Individuals who can come to the designated venue for this study and be inspected. [7]Individuals judged appropriate for the study by the principal. |
|||
| Key exclusion criteria | [1]Individuals using medical products.
[2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [3]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis). [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease. [5]Individuals who are a patient or have a history of or endocrine disease. [6]Individuals whose fasting blood glucose is over 126mg/dL or HbA1c (NGSP) is over 6.5%. [7]Individuals whose systolic and diastolic blood pressures are over 140mmHg and 90mmHg, respectively. [8]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [9]Individuals who experienced unpleasant feeling during blood drawing. [10]Individuals who are sensitive to a test product or other foods, and medical products. [11]Individuals who habitually take the foods for specified health uses (FOSHU) or functional food (except for subjects who can stop consume them after informed consent). [12]Individuals who have a habit to intake a product similar with a test food. [13]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day). [14]Individuals with possible changes of life style, such as conducting a long-term travel, during the test period. [15]Individuals who are or are possibly, or are lactating. [16]Individuals who participated in other clinical studies in the past 3 months. [17]Individuals who cannot refrain from eating between meals. [18]Individuals who are or whose family is engaged in functional foods or cosmetics. [19]Individuals judged inappropriate for the study by the principal. |
|||
| Target sample size | 24 | |||
| Research contact person | |
| Name of lead principal investigator | Mamoru Oki |
| Organization | Seishukai Medical Corporation Seishukai Hospital |
| Division name | Head |
| Address | 3-18-5 Matsugaya Taito-ku Tokyo 111-0036, JAPAN |
| TEL | 03-3847-8866 |
| info@tes-h.co.jp | |
| Public contact | |
| Name of contact person | Ryoma Shimizu |
| Organization | TES Holdings Co., Ltd |
| Division name | Administrative Department of Clinical Trials |
| Address | 6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN |
| TEL | +81-3-6801-8480 |
| Homepage URL | |
| r.shimizu@tes-h.co.jp | |
| Sponsor | |
| Institute | TES Holdings Co., Ltd |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Hakkaisan Brewery Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035617 |